Search

Your search keyword '"Wildenbeest, Joanne"' showing total 330 results
Start Over Author "Wildenbeest, Joanne"
330 results on '"Wildenbeest, Joanne"'

1. Nasal cathelicidin is expressed in early life and is increased during mild, but not severe respiratory syncytial virus infection

Author

Sintoris, Sofia, Binkowska, Justyna M., Gillan, Jonathan L., Zuurbier, Roy P., Twynam-Perkins, Jonathan, Kristensen, Maartje, Melrose, Lauren, Parga, Paula Lusaretta, Rodriguez, Alicia Ruiz, Chu, Mei Ling, van Boeckel, Sara R., Wildenbeest, Joanne G., Bowdish, Dawn M. E., Currie, Andrew J., Thwaites, Ryan S., Schwarze, Jurgen, van Houten, Marlies A., Boardman, James P., Cunningham, Steve, Bogaert, Debby, and Davidson, Donald J.

Published
2024
Full Text
View/download PDF

3. Age-specific SARS-CoV-2 transmission differed from human rhinovirus in households during the early COVID-19 pandemic

Author

Boom, Trisja T., de Hoog, Marieke L.A., Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie D., Fourie, Elandri, Sluiter-Post, Judith G.C., Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Sanders, Elisabeth A.M., Eggink, Dirk, Reusken, Chantal, Bont, Louis J., Wildenbeest, Joanne G., van Houten, Marlies A., Duijts, Liesbeth, and Bruijning-Verhagen, Patricia C.J.L.

Published
2024
Full Text
View/download PDF

5. Serum proteomics reveals hemophagocytic lymphohistiocytosis-like phenotype in a subset of patients with multisystem inflammatory syndrome in children

Author

Tulling, Adam J., Holierhoek, Marloes G., Jansen-Hoogendijk, Anja M., Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J., Oostenbrink, Rianne, Buysse, Corinne M.P., Bannier, Michiel A.G.E., Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C., Jacobs, Monique A.M., Kamps, Arvid W.A., van der Linden, Jan W., Lebon, Ankie, Oudshoorn, Johanna H., Tramper-Stranders, Gerdien A., Vastert, Sebastiaan J., Wieringa, Jantien W., Terheggen-Lagro, Suzanne W.J., Wildenbeest, Joanne G., von Asmuth, Erik G.J., van den Akker, Erik B., van Gijn, Marielle E., Lugthart, Gertjan, and Buddingh, Emilie P.

Published
2024
Full Text
View/download PDF

8. Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children From Wild-type to Population Immunity: A Prospective Multicenter Cohort Study With Real-time Reporting

Author

Tulling, Adam J., Lugthart, Gertjan, Mooij, Miriam G., Brackel, Caroline L. H., Terheggen-Lagro, Suzanne W. J., Oostenbrink, Rianne, Buysse, Corinne M. P., Hashimoto, Simone, Armbrust, Wineke, Bannier, Michiel A. G. E., Bekhof, Jolita, van Gameren-Oosterom, Helma B., Hendriks, Han, van Houten, Marlies A., van der Linden, Jan W., Lebon, Ankie, van Onzenoort-Bokken, Lonneke, Tramper-Stranders, Gerdien A., van Veen, Mirjam, von Asmuth, Erik G. J., Buddingh, Emilie P., van der Aa, Leontien B., van Aerde, Koen J., Auffarth-Smedema, Bettina, Bart, Ingeborg Y., Beek, Cherise, Bechan, Gitanjali I., van den Berg, J. Merlijn, Boonstra, Venje H., Breukels, Mijke, Brinkman, Danielle M.C., Bruijning-Verhagen, Patricia C.J.L., de Crom, Stephanie C., Ernst-Kruis, Margot R., Fraaij, Pieter L.A., Goris, Joyce, Groeneweg, Michael, Gruppen, Mariken, Hammer, Sanne C., Hissink Muller, Petra C.E., Homan-van der Veen, Jenneke, Jacobs, Monique A.M., Kamps, Arvid W.A., Ketharanathan, Naomi, van der Kuip, Martijn, Kuijpers, Taco W., Legger, Elizabeth G., Lo-A-Njoe, Shirley, Manshande, Meindert E., Miedema, Carien J., Obihara, Charlie C., Olivieira, Gideon O., Oudshoorn, Annemarie, Peeters, Esther J.E., Petru, Ronald, Pijnenburg, Marielle W.H., Rook, Denise, Schilleman, Kim, Schopmeijer, Rian, Slotboom, David, van der Steen, Manouk, Stol, Kim, Thomasse, Yolande E.M., Tissing, Wim J.E., van den Tweel, Xandra W., Vastert, Sebastiaan J., Verbeek, Anne B., Vernooij-van Langen, Annette M.M., Wieringa, Jantien W., Wildenbeest, Joanne G., de Wildt, Saskia N., and van Woerden, Christiaan

Published
2023
Full Text
View/download PDF

9. Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study

Author

Ohm, Milou, van Straalen, Joeri W., Zijlstra, Marieke, de Joode-Smink, Gerrie, Sellies, Anne Jasmijn, Swart, Joost F., Vastert, Sebastiaan J., van Montfrans, Joris M., Bartels, Marije, van Royen-Kerkhof, Annet, Wildenbeest, Joanne G., Lindemans, Caroline A., Wolters, Victorien M., Wennink, Roos A.W., de Boer, Joke H., Knol, Mirjam J., Heijstek, Marloes W., Sanders, Elisabeth A.M., Verduyn-Lunel, Frans M., Berbers, Guy A.M., Wulffraat, Nico M., and Jansen, Marc H.A.

Published
2023
Full Text
View/download PDF

11. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Author

Mazur, Natalie I, Terstappen, Jonne, Baral, Ranju, Bardají, Azucena, Beutels, Philippe, Buchholz, Ursula J, Cohen, Cheryl, Crowe, James E, Jr, Cutland, Clare L, Eckert, Linda, Feikin, Daniel, Fitzpatrick, Tiffany, Fong, Youyi, Graham, Barney S, Heikkinen, Terho, Higgins, Deborah, Hirve, Siddhivinayak, Klugman, Keith P, Kragten-Tabatabaie, Leyla, Lemey, Philippe, Libster, Romina, Löwensteyn, Yvette, Mejias, Asuncion, Munoz, Flor M, Munywoki, Patrick K, Mwananyanda, Lawrence, Nair, Harish, Nunes, Marta C, Ramilo, Octavio, Richmond, Peter, Ruckwardt, Tracy J, Sande, Charles, Srikantiah, Padmini, Thacker, Naveen, Waldstein, Kody A, Weinberger, Dan, Wildenbeest, Joanne, Wiseman, Dexter, Zar, Heather J, Zambon, Maria, and Bont, Louis

Published
2023
Full Text
View/download PDF

12. Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials

Author

Marie-Noelle Billard, Rengerink, Katrien Oude, Bont, Louis, Wildenbeest, Joanne, Nair, Harish, Campbell, Harry, Beutels, Philippe, Openshaw, Peter, Pollard, Andrew, Martinon-Torres, Federico, Heikkinen, Terho, Meijer, Adam, Fischer, Thea Kølsen, van den Berge, Maarten, Giaquinto, Carlo, Aerssens, Jeroen, Abram, Michael, Swanson, Kena, Demont, Clarisse, Gallichan, Scott, Kumar, Veena, Stoszek, Sonia, Molero, Eva, Billard, Marie-Noëlle, Bont, Louis J., McCracken, John P., and Oude Rengerink, Katrien

Published
2022
Full Text
View/download PDF

13. Serum and mucosal antibodymediated protection and identification of asymptomatic respiratory syncytial virus infection in community-dwelling older adults in Europe.

Author

Öner, Deniz, Vernhes, Charlotte, Balla-Jhagjhoorsingh, Sunita, Moureau, Annick, Crabbe, Marjolein, Salaun, Bruno, Bastian, Arangassery Rosemary, Thys, Kim, De Smedt, Jonathan, Ooft, Salo N., Korsten, Koos, Adriaenssens, Niels, Coenen, Samuel, Butler, Christopher C., Verheij, Theo J. M., Drysdale, Simon B., Wildenbeest, Joanne G., Pollard, Andrew J., Openshaw, Peter J. M., and Bont, Louis

Subjects
RESPIRATORY syncytial virus infections, RESPIRATORY infections, RECEIVER operating characteristic curves, RESPIRATORY syncytial virus, OLDER people
Abstract

Introduction: Respiratory syncytial virus (RSV) causes acute respiratory tract infection (ARTI) and reinfects adults throughout life, posing a risk for hospitalization in older adults (>60 years) with frailty and comorbidities. Methods: To investigate serum and mucosal antibodies for protection against RSV infections, baseline serum samples were compared for RSV-pre- and -postfusion (F) binding, and RSV-A2 neutralizing IgG antibodies between symptomatic RSV-ARTI (N = 30), non-RSV (RSV negative) ARTI (N = 386), and no ARTI (N = 338). Mucosal RSV-pre-F IgA and IgG levels, as well as serum RSV-G IgG antibodies, were analyzed to determine their association with protection from symptomatic RSV-ARTI in a subset study. Results: Using a receiver operating characteristic (ROC) analysis, we established thresholds of 1.4- to 1.6-fold change (FC) for RSV-pre-F and -post-F, and RSV-A2 neutralizing IgG antibodies, respectively, enabling the identification of asymptomatic RSV cases with high sensitivity and specificity (>80% and >90%, respectively). As a result, serum RSV-pre-F, RSV-G IgG, and mucosal pre-F binding IgA antibodies showed correlations with protection against symptomatic RSV infection. RSV-pre-F IgG antibodies were correlated with protection from RSV infections irrespective of the symptoms. Discussion: This study provides insights into antibody-mediated protection for symptomatic RSV infection in a community-dwelling older-adult population and establishes a threshold to identify asymptomatic RSV infection using a datadriven approach. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Respiratory Syncytial Virus–related Community Chronic Obstructive Pulmonary Disease Exacerbations and Novel Diagnostics: A Binational Prospective Cohort Study.

Author

Wiseman, Dexter J., Thwaites, Ryan S., Ritchie, Andrew I., Finney, Lydia, Macleod, Mairi, Kamal, Faisal, Shahbakhti, Hassan, van Smoorenburg, Lisa H., Kerstjens, Hiub A. M., Wildenbeest, Joanne, Öner, Deniz, Aerssens, Jeroen, Berbers, Guy, Schepp, Rutger, Uruchurtu, Ashley, Ditz, Benedikt, Bont, Louis, Allinson, James P., van den Berge, Maarten, and Donaldson, Gavin C.

Subjects
RESPIRATORY syncytial virus infections, CHRONIC obstructive pulmonary disease, RESPIRATORY syncytial virus infection vaccines, RESPIRATORY syncytial virus, DISEASE exacerbation
Abstract

Rationale: Respiratory syncytial virus (RSV) is a common global respiratory virus that is increasingly recognized as a major pathogen in frail older adults and as a cause of chronic obstructive pulmonary disease (COPD) exacerbations. There is no single test for RSV in adults that has acceptable diagnostic accuracy. Trials of RSV vaccines have recently shown excellent safety and efficacy against RSV in older adults; defining the frequency of RSV-related community infections and COPD exacerbations is important for vaccine deployment decisions. Objectives: This prospective study aimed to establish the frequency of outpatient-managed RSV-related exacerbations of COPD in two well-characterized patient cohorts using a combination of diagnostic methods. Methods: Participants were recruited at specialist clinics in London, United Kingdom, and Groningen, the Netherlands, beginning in 2017 and observed for three consecutive RSV seasons, during exacerbations, and at least twice yearly. RSV infections were detected by RT-PCR and serologic testing. Measurements and Main Results: A total of 377 patients with COPD attended 1,999 clinic visits and reported 310 exacerbations. There were 27 RSV-related exacerbations (8.7% of the total); of these, seven were detected only by PCR, 16 only by serology, and four by both methods. Increases in RSV-specific Nucleoprotein antibody were as sensitive as those in the antibody to Pre-Fusion or Post-Fusion for serodiagnosis of RSV-related exacerbations. Conclusions: RSV is associated with 8.7% of outpatient-managed COPD exacerbations in this study. Antibodies to RSV Nucleoprotein may have diagnostic value and are potentially important in a vaccinated population. The introduction of vaccines that prevent RSV is expected to benefit patients with COPD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Age-specific SARS-CoV-2 transmission differed from human rhinovirus in households during the early COVID-19 pandemic

Author

Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Methodologie, Child Health, Onderzoek, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, JC onderzoeksprogramma Infectieziekten, Boom, Trisja T, de Hoog, Marieke L A, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie D, Fourie, Elandri, Sluiter-Post, Judith G C, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Sanders, Elisabeth A M, Eggink, Dirk, Reusken, Chantal, Bont, Louis J, Wildenbeest, Joanne G, van Houten, Marlies A, Duijts, Liesbeth, Bruijning-Verhagen, Patricia C J L, Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Methodologie, Child Health, Onderzoek, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, JC onderzoeksprogramma Infectieziekten, Boom, Trisja T, de Hoog, Marieke L A, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie D, Fourie, Elandri, Sluiter-Post, Judith G C, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Sanders, Elisabeth A M, Eggink, Dirk, Reusken, Chantal, Bont, Louis J, Wildenbeest, Joanne G, van Houten, Marlies A, Duijts, Liesbeth, and Bruijning-Verhagen, Patricia C J L

Published
2024

16. Nasal cathelicidin is expressed in early life and is increased during mild, but not severe respiratory syncytial virus infection

Author

Infectieziekten onderzoek1 (Bont), Infectieziekten onderzoek3 (Bogaert), Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Onderzoek, Sintoris, Sofia, Binkowska, Justyna M., Gillan, Jonathan L., Zuurbier, Roy P., Twynam-Perkins, Jonathan, Kristensen, Maartje, Melrose, Lauren, Parga, Paula Lusaretta, Rodriguez, Alicia Ruiz, Chu, Mei Ling, van Boeckel, Sara R., Wildenbeest, Joanne G., Bowdish, Dawn M.E., Currie, Andrew J., Thwaites, Ryan S., Schwarze, Jurgen, van Houten, Marlies A., Boardman, James P., Cunningham, Steve, Bogaert, Debby, Davidson, Donald J., Infectieziekten onderzoek1 (Bont), Infectieziekten onderzoek3 (Bogaert), Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Onderzoek, Sintoris, Sofia, Binkowska, Justyna M., Gillan, Jonathan L., Zuurbier, Roy P., Twynam-Perkins, Jonathan, Kristensen, Maartje, Melrose, Lauren, Parga, Paula Lusaretta, Rodriguez, Alicia Ruiz, Chu, Mei Ling, van Boeckel, Sara R., Wildenbeest, Joanne G., Bowdish, Dawn M.E., Currie, Andrew J., Thwaites, Ryan S., Schwarze, Jurgen, van Houten, Marlies A., Boardman, James P., Cunningham, Steve, Bogaert, Debby, and Davidson, Donald J.

Published
2024

17. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants

Author

CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Johnson, Mari, Chelysheva, Irina, Öner, Deniz, McGinley, Joseph, Lin, Gu-Lung, O'Connor, Daniel, Robinson, Hannah, Drysdale, Simon B, Gammin, Emma, Vernon, Sophie, Muller, Jill, Wolfenden, Helen, Westcar, Sharon, Anguvaa, Lazarus, Thwaites, Ryan S, Bont, Louis, Wildenbeest, Joanne, Martinón-Torres, Federico, Aerssens, Jeroen, Openshaw, Peter J M, Pollard, Andrew J, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Johnson, Mari, Chelysheva, Irina, Öner, Deniz, McGinley, Joseph, Lin, Gu-Lung, O'Connor, Daniel, Robinson, Hannah, Drysdale, Simon B, Gammin, Emma, Vernon, Sophie, Muller, Jill, Wolfenden, Helen, Westcar, Sharon, Anguvaa, Lazarus, Thwaites, Ryan S, Bont, Louis, Wildenbeest, Joanne, Martinón-Torres, Federico, Aerssens, Jeroen, Openshaw, Peter J M, and Pollard, Andrew J

Published
2024

18. Healthcare costs related to respiratory syncytial virus in paediatric intensive care units in the Netherlands: a nationwide prospective observational study (the BRICK study)

Author

Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Intensive care patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, HEE, JC onderzoeksprogramma Methodologie, Phijffer, Emily W.E.M., Wildenbeest, Joanne G., Brouwer, Carole N.M., de Hoog, Matthijs, Kneyber, Martin C.J., Maebe, Sofie, Nusmeier, Anneliese, Riedijk, Maaike A., Wösten-van Asperen, Roelie M., van Woensel, Job B.M., Bont, Louis J., Frederix, Geert J.W., Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Intensive care patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, HEE, JC onderzoeksprogramma Methodologie, Phijffer, Emily W.E.M., Wildenbeest, Joanne G., Brouwer, Carole N.M., de Hoog, Matthijs, Kneyber, Martin C.J., Maebe, Sofie, Nusmeier, Anneliese, Riedijk, Maaike A., Wösten-van Asperen, Roelie M., van Woensel, Job B.M., Bont, Louis J., and Frederix, Geert J.W.

Published
2024

19. Serum proteomics reveals hemophagocytic lymphohistiocytosis-like phenotype in a subset of patients with multisystem inflammatory syndrome in children

Author

CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Genetica Sectie Genoomdiagnostiek, Tulling, Adam J, Holierhoek, Marloes G, Jansen-Hoogendijk, Anja M, Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J, Oostenbrink, Rianne, Buysse, Corinne M P, Bannier, Michiel A G E, Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C, Jacobs, Monique A M, Kamps, Arvid W A, van der Linden, Jan W, Lebon, Ankie, Oudshoorn, Johanna H, Tramper-Stranders, Gerdien A, Vastert, Sebastiaan J, Wieringa, Jantien W, Terheggen-Lagro, Suzanne W J, Wildenbeest, Joanne G, von Asmuth, Erik G J, van den Akker, Erik B, van Gijn, Marielle E, Lugthart, Gertjan, Buddingh, Emilie P, CTI Van Loosdregt, Immuno/reuma onderzoek 1 (Vastert), Immunologie/Reumatologie, Child Health, Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Genetica Sectie Genoomdiagnostiek, Tulling, Adam J, Holierhoek, Marloes G, Jansen-Hoogendijk, Anja M, Hoste, Levi, Haerynck, Filomeen, Tavernier, Simon J, Oostenbrink, Rianne, Buysse, Corinne M P, Bannier, Michiel A G E, Bekhof, Jolita, Breukels, Mijke, Hammer, Sanne C, Jacobs, Monique A M, Kamps, Arvid W A, van der Linden, Jan W, Lebon, Ankie, Oudshoorn, Johanna H, Tramper-Stranders, Gerdien A, Vastert, Sebastiaan J, Wieringa, Jantien W, Terheggen-Lagro, Suzanne W J, Wildenbeest, Joanne G, von Asmuth, Erik G J, van den Akker, Erik B, van Gijn, Marielle E, Lugthart, Gertjan, and Buddingh, Emilie P

Published
2024

20. Healthcare costs related to respiratory syncytial virus in paediatric intensive care units in the Netherlands:a nationwide prospective observational study (the BRICK study)

Author

Phijffer, Emily W.E.M., Wildenbeest, Joanne G., Brouwer, Carole N.M., de Hoog, Matthijs, Kneyber, Martin C.J., Maebe, Sofie, Nusmeier, Anneliese, Riedijk, Maaike A., Wösten-van Asperen, Roelie M., van Woensel, Job B.M., Bont, Louis J., Frederix, Geert J.W., Phijffer, Emily W.E.M., Wildenbeest, Joanne G., Brouwer, Carole N.M., de Hoog, Matthijs, Kneyber, Martin C.J., Maebe, Sofie, Nusmeier, Anneliese, Riedijk, Maaike A., Wösten-van Asperen, Roelie M., van Woensel, Job B.M., Bont, Louis J., and Frederix, Geert J.W.

Abstract

Background: The implementation of the approved respiratory syncytial virus (RSV) preventive interventions in immunisation programmes is advancing rapidly. Insight into healthcare costs of RSV-related paediatric intensive care unit (PICU) admissions is lacking, but of great importance to evaluate the impact of implementation. Therefore, this study aimed to determine the total annual RSV-related paediatric intensive care healthcare costs in the Netherlands. Methods: A nationwide prospective, observational, multicenter study was performed from September 2021 until June 2023. The total annual RSV-related healthcare costs on PICUs in the Netherlands were calculated using RSV-related costs (subgroup I) and consequential costs (subgroup II and III). Subgroup I comprised all PICU admitted infants ≤12 months of age with laboratory-confirmed RSV infection. Subgroup II and III consisted of postponed elective PICU admissions and refused acute PICU admissions due to RSV-related lack of PICU capacity.Findings: A total of 424 infants with RSV-related PICU admission were included. Median age at PICU admission was 46 days (IQR 25–89). The median length of PICU admission was 5 days (IQR 3–8). The total RSV-related PICU costs are € 3,826,386 in 2021–2022, and € 3,183,888 in 2022–2023. Potential costs averted by RSV preventive interventions is € 1.9 to € 2.6 million depending on season, and the duration of protection. Interpretation: RSV-related PICU admissions cost €3.1 to €3.8 million in the Netherlands during one season. The introduction of new RSV preventive interventions into the Dutch immunisation programme will generate significant cost-savings on PICUs and decreases the admission burden of PICUs.

Published
2024

21. Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study

Author

Van Boven, Michiel, van Dorp, Christiaan H., Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A., Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J., Kretzschmar, Mirjam E., Bruijning-Verhagen, Patricia, Van Boven, Michiel, van Dorp, Christiaan H., Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A., Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J., Kretzschmar, Mirjam E., and Bruijning-Verhagen, Patricia

Abstract

Household studies provide an efficient means to study transmission of infectious diseases, enabling estimation of susceptibility and infectivity by person-type. A main inclusion criterion in such studies is usually the presence of an infected person. This precludes estimation of the hazards of pathogen introduction into the household. Here we estimate age- and time-dependent household introduction hazards together with within household transmission rates using data from a prospective household-based study in the Netherlands. A total of 307 households containing 1, 209 persons were included from August 2020 until March 2021. Follow-up of households took place between August 2020 and August 2021 with maximal follow-up per household mostly limited to 161 days. Almost 1 out of 5 households (59/307) had evidence of an introduction of SARS-CoV-2. We estimate introduction hazards and within-household transmission rates in our study population with penalized splines and stochastic epidemic models, respectively. The estimated hazard of introduction of SARS-CoV-2 in the households was lower for children (0-12 years) than for adults (relative hazard: 0.62; 95%CrI: 0.34-1.0). Estimated introduction hazards peaked in mid October 2020, mid December 2020, and mid April 2021, preceding peaks in hospital admissions by 1-2 weeks. Best fitting transmission models included increased infectivity of children relative to adults and adolescents, such that the estimated child-to-child transmission probability (0.62; 95%CrI: 0.40-0.81) was considerably higher than the adult-to-adult transmission probability (0.12; 95%CrI: 0.057-0.19). Scenario analyses indicate that vaccination of adults can strongly reduce household infection attack rates and that adding adolescent vaccination offers limited added benefit.

Published
2024

22. Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study

Author

Epi Infectieziekten, Infection & Immunity, Epi Infectieziekten Team 1, Child Health, JC onderzoeksprogramma Methodologie, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Epi Infectieziekten Team 2, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, van Boven, Michiel, van Dorp, Christiaan H, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J, Kretzschmar, Mirjam E, Bruijning-Verhagen, Patricia, Epi Infectieziekten, Infection & Immunity, Epi Infectieziekten Team 1, Child Health, JC onderzoeksprogramma Methodologie, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Epi Infectieziekten Team 2, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, van Boven, Michiel, van Dorp, Christiaan H, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J, Kretzschmar, Mirjam E, and Bruijning-Verhagen, Patricia

Published
2024

23. Outpatient respiratory syncytial virus infections and novel preventive interventions

Author

Infectieziekten onderzoek2 (Wildenbeest), Infection & Immunity, HAG Onderzoek, Child Health, Infectieziekten patientenzorg, Infectieziekten onderzoek1 (Bont), CTI Bont, Hak, Sarah F, Venekamp, Roderick P, Wildenbeest, Joanne G, Bont, Louis J, Infectieziekten onderzoek2 (Wildenbeest), Infection & Immunity, HAG Onderzoek, Child Health, Infectieziekten patientenzorg, Infectieziekten onderzoek1 (Bont), CTI Bont, Hak, Sarah F, Venekamp, Roderick P, Wildenbeest, Joanne G, and Bont, Louis J

Published
2024

24. External Validation of the Discriminative Validity of the ReSVinet Score and Development of Simplified ReSVinet Scores in Secondary Care

Author

Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Infection & Immunity, CTI Bont, Infectieziekten onderzoek1 (Bont), Sheikh, Zakariya, Potter, Ellie, Li, You, Drysdale, Simon B, Wildenbeest, Joanne G, Robinson, Hannah, McGinley, Joseph, Lin, Gu-Lung, Öner, Deniz, Aerssens, Jeroen, Justicia-Grande, Antonio José, Martinón-Torres, Federico, Pollard, Andrew J, Bont, Louis, Nair, Harish, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Infection & Immunity, CTI Bont, Infectieziekten onderzoek1 (Bont), Sheikh, Zakariya, Potter, Ellie, Li, You, Drysdale, Simon B, Wildenbeest, Joanne G, Robinson, Hannah, McGinley, Joseph, Lin, Gu-Lung, Öner, Deniz, Aerssens, Jeroen, Justicia-Grande, Antonio José, Martinón-Torres, Federico, Pollard, Andrew J, Bont, Louis, and Nair, Harish

Published
2024

25. Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes

Author

Infectieziekten onderzoek2 (Wildenbeest), MS Verloskunde, Infection & Immunity, Infectieziekten patientenzorg, Child Health, CTI Bont, Infectieziekten onderzoek1 (Bont), Epidemiology & Health Economics, Data Science & Biostatistiek, RWE/Causal inference, Geboortecentrum voorzitterschap, Phijffer, Emily, de Bruin, Odette, Wildenbeest, Joanne G., Bont, Louis J., Sturkenboom, Miriam C.J.M., Van der Maas, Nicoline A.T., Ahmadizar, Fariba, Bloemenkamp, Kitty W.M., Infectieziekten onderzoek2 (Wildenbeest), MS Verloskunde, Infection & Immunity, Infectieziekten patientenzorg, Child Health, CTI Bont, Infectieziekten onderzoek1 (Bont), Epidemiology & Health Economics, Data Science & Biostatistiek, RWE/Causal inference, Geboortecentrum voorzitterschap, Phijffer, Emily, de Bruin, Odette, Wildenbeest, Joanne G., Bont, Louis J., Sturkenboom, Miriam C.J.M., Van der Maas, Nicoline A.T., Ahmadizar, Fariba, and Bloemenkamp, Kitty W.M.

Published
2024

26. IgG1 glycosylation highlights premature aging in Down syndrome.

Author

Streng, Bianca M. M., Van Coillie, Julie, Wildenbeest, Joanne G., Binnendijk, Rob S., Smits, Gaby, den Hartog, Gerco, Wang, Wenjun, Nouta, Jan, Linty, Federica, Visser, Remco, Wuhrer, Manfred, Vidarsson, Gestur, and Bont, Louis J.

Subjects
PREMATURE aging (Medicine), LIQUID chromatography-mass spectrometry, DOWN syndrome, GLYCOSYLATION, IMMUNE response, FUCOSYLATION
Abstract

Down syndrome (DS) is characterized by lowered immune competence and premature aging. We previously showed decreased antibody response following SARS‐CoV‐2 vaccination in adults with DS. IgG1 Fc glycosylation patterns are known to affect the effector function of IgG and are associated with aging. Here, we compare total and anti‐spike (S) IgG1 glycosylation patterns following SARS‐CoV‐2 vaccination in DS and healthy controls (HC). Total and anti‐Spike IgG1 Fc N‐glycan glycoprofiles were measured in non‐exposed adults with DS and controls before and after SARS‐CoV‐2 vaccination by liquid chromatography–mass spectrometry (LC–MS) of Fc glycopeptides. We recruited N = 44 patients and N = 40 controls. We confirmed IgG glycosylation patterns associated with aging in HC and showed premature aging in DS. In DS, we found decreased galactosylation (50.2% vs. 59.0%) and sialylation (6.7% vs. 8.5%) as well as increased fucosylation (97.0% vs. 94.6%) of total IgG. Both cohorts showed similar bisecting GlcNAc of total and anti‐S IgG1 with age. In contrast, anti‐S IgG1 of DS and HC showed highly comparable glycosylation profiles 28 days post vaccination. The IgG1 glycoprofile in DS exhibits strong premature aging. The combination of an early decrease in IgG1 Fc galactosylation and sialylation and increase in fucosylation is predicted to reduce complement activity and decrease FcγRIII binding and subsequent activation, respectively. The altered glycosylation patterns, combined with decreased antibody concentrations, help us understand the susceptibility to severe infections in DS. The effect of premature aging highlights the need for individuals with DS to receive tailored vaccines and/or vaccination schedules. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Expert panel diagnosis demonstrated high reproducibility as reference standard in infectious diseases

Author

van Houten, Chantal B., Naaktgeboren, Christiana A., Ashkenazi-Hoffnung, Liat, Ashkenazi, Shai, Avis, Wim, Chistyakov, Irena, Corigliano, Teresa, Galetto, Annick, Gangoiti, Iker, Gervaix, Alain, Glikman, Daniel, Ivaskeviciene, Inga, Kuperman, Amir A., Lacroix, Laurence, Loeffen, Yvette, Luterbacher, Fanny, Meijssen, Clemens B., Mintegi, Santiago, Nasrallah, Basheer, Papan, Cihan, van Rossum, Annemarie M.C., Rudolph, Henriette, Stein, Michal, Tal, Roie, Tenenbaum, Tobias, Usonis, Vytautas, de Waal, Wouter, Weichert, Stefan, Wildenbeest, Joanne G., de Winter-de Groot, Karin M., Wolfs, Tom F.W., Mastboim, Niv, Gottlieb, Tanya M., Cohen, Asi, Oved, Kfir, Eden, Eran, Feigin, Paul D., Shani, Liran, and Bont, Louis J.

Published
2019
Full Text
View/download PDF

31. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants.

Author

Johnson, Mari, Chelysheva, Irina, Öner, Deniz, McGinley, Joseph, Lin, Gu-Lung, O'Connor, Daniel, Robinson, Hannah, Drysdale, Simon B, Gammin, Emma, Vernon, Sophie, Muller, Jill, Wolfenden, Helen, Westcar, Sharon, Anguvaa, Lazarus, Thwaites, Ryan S, Bont, Louis, Wildenbeest, Joanne, Martinón-Torres, Federico, Aerssens, Jeroen, and Openshaw, Peter J M

Subjects
RESPIRATORY syncytial virus infections, GENOME-wide association studies, GENE expression, INFANTS, FALSE discovery rate
Abstract

Background Respiratory syncytial virus (RSV) is a significant cause of infant morbidity and mortality worldwide. Most children experience at least one 1 RSV infection by the age of two 2 years, but not all develop severe disease. However, the understanding of genetic risk factors for severe RSV is incomplete. Consequently, we conducted a genome-wide association study of RSV severity. Methods Disease severity was assessed by the ReSVinet scale, in a cohort of 251 infants aged 1 week to 1 year. Genotyping data were collected from multiple European study sites as part of the RESCEU Consortium. Linear regression models were used to assess the impact of genotype on RSV severity and gene expression as measured by microarray. Results While no SNPs reached the genome-wide statistical significance threshold (P < 5 × 10−8), we identified 816 candidate SNPs with a P -value of <1 × 10−4. Functional annotation of candidate SNPs highlighted genes relevant to neutrophil trafficking and cytoskeletal functions, including LSP1 and RAB27A. Moreover, SNPs within the RAB27A locus significantly altered gene expression (false discovery rate, FDR P <.05). Conclusions These findings may provide insights into genetic mechanisms driving severe RSV infection, offering biologically relevant information for future investigations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Substantial Burden of Nonmedically Attended RSV Infection in Healthy-Term Infants: An International Prospective Birth Cohort Study.

Author

Hak, Sarah F, Venekamp, Roderick P, Billard, Marie-Noëlle, Houten, Marlies A van, Pollard, Andrew J, Heikkinen, Terho, Cunningham, Steve, Millar, Margaret, Martinón-Torres, Federico, Dacosta-Urbieta, Ana, Bont, Louis J, Wildenbeest, Joanne G, and Investigators, PROMISE

Subjects
RESPIRATORY syncytial virus infections, COHORT analysis, RESPIRATORY syncytial virus, INFANTS, CLINICAL trial registries
Abstract

Background During the first year of life, 1 in 4 infants develops a symptomatic respiratory syncytial virus (RSV) infection, yet only half seek medical attention. The current focus on medically attended RSV therefore underrepresents the true societal burden of RSV. We assessed the burden of nonmedically attended RSV infections and compared with medically attended RSV. Methods We performed active RSV surveillance until the age of 1 year in a cohort (n = 993) nested within the Respiratory Syncytial Virus Consortium in EUrope (RESCEU) prospective birth cohort study enrolling healthy term-born infants in 5 European countries. Symptoms, medication use, wheezing, and impact on family life were analyzed. Results For 97 of 120 (80.1%) nonmedically attended RSV episodes, sufficient data were available for analysis. In 50.5% (49/97), symptoms lasted ≥15 days. Parents reported impairment in usual daily activities in 59.8% (58/97) of episodes; worries, 75.3% (73/97); anxiety, 34.0% (33/97); and work absenteeism, 10.8% (10/93). Compared with medically attended RSV (n = 102, 9 hospital admissions), Respiratory Syncytial Virus NETwork (ReSViNET) severity scores were lower (3.5 vs 4.6, P <.001), whereas duration of respiratory symptoms and was comparable. Conclusions Even when medical attendance is not required, RSV infection poses a substantial burden to infants, families, and society. These findings are important for policy makers when considering the implementation of RSV immunization. Clinical Trials Registration. ClinicalTrials.gov (NCT03627572). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. External Validation of the Discriminative Validity of the ReSVinet Score and Development of Simplified ReSVinet Scores in Secondary Care.

Author

Sheikh, Zakariya, Potter, Ellie, Li, You, Drysdale, Simon B, Wildenbeest, Joanne G, Robinson, Hannah, McGinley, Joseph, Lin, Gu-Lung, Öner, Deniz, Aerssens, Jeroen, Justicia-Grande, Antonio José, Martinón-Torres, Federico, Pollard, Andrew J, Bont, Louis, and Nair, Harish

Subjects
BRONCHIOLITIS, SECONDARY care (Medicine), RECEIVER operating characteristic curves, RESOURCE-limited settings, RESPIRATORY syncytial virus, INTENSIVE care units, VACCINES
Abstract

Background There is no consensus on how to best quantify disease severity in infants with respiratory syncytial virus (RSV) and/or bronchiolitis; this lack of a sufficiently validated score complicates the provision of clinical care and, the evaluation of trials of therapeutics and vaccines. The ReSVinet score appears to be one of the most promising; however, it is too time consuming to be incorporated into routine clinical care. We aimed to develop and externally validate simplified versions of this score. Methods Data from a multinational (the Netherlands, Spain, and United Kingdom) multicenter case-control study of infants with RSV were used to develop simplified versions of the ReSVinet score by conducting a grid search to determine the best combination of equally weighted parameters to maximize for the discriminative ability (measured by area under the receiver operating characteristic curve [AUROC]) across a range of outcomes (hospitalization, intensive care unit admission, ventilation requirement). Subsequently discriminative validity of the score for a range of secondary care outcomes was externally validated by secondary analysis of datasets from Rwanda and Colombia. Results Three candidate simplified scores were identified using the development dataset; they were excellent (AUROC >0.9) at discriminating for a range of outcomes, and their performance was not significantly different from the original ReSVinet score despite having fewer parameters. In the external validation datasets, the simplified scores were moderate to excellent (AUROC, 0.7–1) across a range of outcomes. In all outcomes, except in a single dataset for predicting admission to the high-dependency unit, they performed at least as well as the original ReSVinet score. Conclusions The candidate simplified scores developed require further external validation in larger datasets, ideally from resource-limited settings before any recommendation regarding their use. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. T cells, more than antibodies, may prevent symptoms developing from respiratory syncytial virus infections in older adults

Author

Salaun, Bruno, primary, De Smedt, Jonathan, additional, Vernhes, Charlotte, additional, Moureau, Annick, additional, Öner, Deniz, additional, Bastian, Arangassery Rosemary, additional, Janssens, Michel, additional, Balla-Jhagjhoorsingh, Sunita, additional, Aerssens, Jeroen, additional, Lambert, Christophe, additional, Coenen, Samuel, additional, Butler, Christopher C., additional, Drysdale, Simon B., additional, Wildenbeest, Joanne G., additional, Pollard, Andrew J., additional, Openshaw, Peter J. M., additional, and Bont, Louis, additional

Published
2023
Full Text
View/download PDF

36. External validation of the discriminative validity of the ReSVinet score & development of simplified ReSVinet scores in secondary care

Author

Sheikh, Zakariya, primary, Potter, Ellie, additional, Li, You, additional, Drysdale, Simon B, additional, Wildenbeest, Joanne G, additional, Robinson, Hannah, additional, McGinley, Joseph, additional, Lin, Gu-Lung, additional, Öner, Deniz, additional, Aerssens, Jeroen, additional, Justicia-Grande, Antonio José, additional, Martinón-Torres, Federico, additional, Pollard, Andrew J, additional, Bont, Louis, additional, and Nair, Harish, additional

Published
2023
Full Text
View/download PDF

39. Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study

Author

van Boven, Michiel, primary, van Dorp, Christiaan H., additional, Westerhof, Ilse, additional, Jaddoe, Vincent, additional, Heuvelman, Valerie, additional, Duijts, Liesbeth, additional, Fourie, Elandri, additional, Sluiter-Post, Judith, additional, van Houten, Marlies A., additional, Badoux, Paul, additional, Euser, Sjoerd, additional, Herpers, Bjorn, additional, Eggink, Dirk, additional, Boom, Trisja, additional, Wildenbeest, Joanne, additional, Bont, Louis, additional, Rozhnova, Ganna, additional, Bonten, Marc J., additional, Kretzschmar, Mirjam E., additional, and Bruijning-Verhagen, Patricia, additional

Published
2023
Full Text
View/download PDF

40. Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults

Author

Mao, Zhuxin, Li, Xiao, Korsten, Koos, Bont, Louis, Butler, Christopher, Wildenbeest, Joanne, Coenen, Samuel, Hens, Niel, Bilcke, Joke, Beutels, Philippe, Nair, Harish, Campbell, Harry, Pollard, Andrew, Openshaw, Peter, Martinon-Torres, Federico, Heikkinen, Terho, Meijer, Adam, Fischer, Thea K, van den Berge, Maarten, Giaquinto, Carlo, Abram, Michael, Swanson, Kena, Rizkalla, Bishoy, Vernhes, Charlotte, Gallichan, Scott, Aerssens, Jeroen, Kumar, Veena, Molero, Eva, Coenen, Samuel/0000-0002-1238-8052, Mao, Zhuxin, Li, Xiao, Korsten, Koos, BONTE, Luis, Butler, Christopher, Wildenbeest, Joanne, COENEN, Samuel, HENS, Niel, Bilcke, Joke, Beutels, Philippe, and RESCEU Investigators

Subjects
Financial Stress, Respiratory Syncytial Virus Infections, elderly, cost, EQ5D, Influenza, Human, Humans, Immunology and Allergy, Biology, Aged, flu, RSV, Middle Aged, outpatients, health-related quality of life, Hospitalization, productivity loss, Infectious Diseases, Respiratory Syncytial Virus, Human, influenza, prospective study, Independent Living, Quality of Life, Human medicine, Respiratory Syncytial Virus, costproductivity loss, Human
Abstract

Background Respiratory syncytial virus (RSV) and influenza virus infections result in a considerable mortality and morbidity among the aging population globally. Influenza vaccination for older adults before the seasonal influenza epidemic has been evaluated to be cost-effective in many countries. Interventions against RSV in older adults are in the pipeline, and evaluating their cost-effectiveness is crucial for decision making. To inform such evaluations, our aim was to estimate average costs and health-related quality of life (HRQoL) in older adults with RSV and influenza infection. Methods The European RESCEU observational cohort study followed 1040 relatively healthy community-dwelling older adults aged 60 years and older during 2 consecutive winter seasons. Health care resource use and HRQoL were collected and analyzed during RSV episodes, and also during influenza episodes. Country-specific unit cost data were mainly obtained from national databases. Direct costs were estimated from a patient, health care provider, and health care payers’ perspective, whereas indirect costs were estimated from a societal perspective. Due to small sample size, no formal statistical comparisons were made. Results Thirty-six RSV and 60 influenza episodes were reported, including 1 hospitalization. Means (median; first-third quartile) of €26.4 (€5.5; 0–47.3) direct and €4.4 (€0; 0–0) indirect costs were reported per nonhospitalized RSV episode, and €42.5 (€36; 3.3–66.7) direct and €32.1 (€0; 0–0) indirect costs per nonhospitalized influenza episode. For RSV episodes, the utility value decreased from 0.896 (0.928; 0.854–0.953) to 0.801 (0.854; 0.712–0.937) from preseason to 1 week after symptom onset; for influenza, the change was from 0.872 (0.895; 0.828–0.953) to 0.664 (0.686; 0.574–0.797). Conclusions The average costs and HRQoL estimates of older adults treated outside the hospital can be used to inform the design of future studies and the decision making regarding interventions to prevent RSV infection in older adults. Larger studies are needed to provide better country-specific and complementary cost estimates and to allow for formal statistical comparison of costs between RSV and influenza. Clinical Trials Registration NCT03621930.

Published
2022

41. Global molecular diversity of RSV – the “INFORM RSV” study

Author

Langedijk, Annefleur C., Lebbink, Robert Jan, Naaktgeboren, Christiana, Evers, Anouk, Viveen, Marco C., Greenough, Anne, Heikkinen, Terho, Stein, Renato T., Richmond, Peter, Martinón-Torres, Federico, Nunes, Marta, Hosoya, Mitsuaki, Keller, Christian, Bauck, Monika, Cohen, Robert, Papenburg, Jesse, Pernica, Jeffrey, Hennus, Marije P., Jin, Hong, Tabor, David E., Tovchigrechko, Andrev, Ruzin, Alexey, Abram, Michael E., Wilkins, Deidre, Wildenbeest, Joanne G., Kragten-Tabatabaie, Leyla, Coenjaerts, Frank E. J., Esser, Mark T., and Bont, Louis J.

Published
2020
Full Text
View/download PDF

42. Single‐cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.

Author

Zivanovic, Nevena, Öner, Deniz, Abraham, Yann, McGinley, Joseph, Drysdale, Simon B., Wildenbeest, Joanne G., Crabbe, Marjolein, Vanhoof, Greet, Thys, Kim, Thwaites, Ryan S., Robinson, Hannah, Bont, Louis, Openshaw, Peter J. M., Martinón‐Torres, Federico, Pollard, Andrew J., and Aerssens, Jeroen

Subjects
RESPIRATORY syncytial virus infections, INFANT diseases, RESPIRATORY syncytial virus, B cells
Abstract

Whereas most infants infected with respiratory syncytial virus (RSV) show no or only mild symptoms, an estimated 3 million children under five are hospitalized annually due to RSV disease. This study aimed to investigate biological mechanisms and associated biomarkers underlying RSV disease heterogeneity in young infants, enabling the potential to objectively categorize RSV‐infected infants according to their medical needs. Immunophenotypic and functional profiling demonstrated the emergence of immature and progenitor‐like neutrophils, proliferative monocytes (HLA‐DRLow, Ki67+), impaired antigen‐presenting function, downregulation of T cell response and low abundance of HLA‐DRLow B cells in severe RSV disease. HLA‐DRLow monocytes were found as a hallmark of RSV‐infected infants requiring hospitalization. Complementary transcriptomics identified genes associated with disease severity and pointed to the emergency myelopoiesis response. These results shed new light on mechanisms underlying the pathogenesis and development of severe RSV disease and identified potential new candidate biomarkers for patient stratification. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Contact With Young Children Increases the Risk of Respiratory Infection in Older Adults in Europe—the RESCEU Study

Author

Korsten, Koos, Adriaenssens, Niels, Coenen, Samuel, Butler, Chris C, Pirçon, Jean-Yves, Verheij, Theo J M, Bont, Louis J, Wildenbeest, Joanne G, Butler, Christopher, Verheij, Theo, Bont, Louis, Wildenbeest, Joanne, Nair, Harish, Campbell, Harry, Beutels, Philippe, Openshaw, Peter, Pollard, Andrew, Molero, Eva, Meijer, Adam, Fischer, Thea K, van den Berge, Maarten, Giaquinto, Carlo, Abram, Michael, Aerssens, Jeroen, Swanson, Kena, Gruselle, Olivier, Leach, Amanda, Stoszek, Sonia, Demont, Clarisse, Gallichan, Scott, Pavot, Vincent, Vernhes, Charlotte, Kumar, Veena, and RESCEU Investigators

Subjects
Europe, Infectious Diseases, Child, Preschool, Odds Ratio, Humans, Infant, Immunology and Allergy, Human medicine, Respiratory Tract Infections, Biology, Aged
Abstract

Background Knowledge about how older adults get a respiratory infection is crucial for planning preventive strategies. We aimed to determine how contact with young children living outside of the household affects the risk of acute respiratory tract infections (ARTI) in community-dwelling older adults. Methods This study is part of the European RESCEU older adult study. Weekly surveillance was performed to detect ARTI throughout 2 winter seasons (2017-2018, 2018-2019). Child exposure, defined as having regular contact with children under 5 living outside of the subject’s household, was assessed at baseline. The average attributable fraction was calculated to determine the fraction of ARTI explained by exposure to these children. Results We prospectively established that 597/1006 (59%) participants experienced at least 1 ARTI. Child exposure increased the risk of all-cause ARTI (adjusted odds ratio [aOR], 1.58; 95% confidence interval [CI], 1.21 -2.08; P = .001). This risk was highest in those with the most frequent contact (aOR, 1.80; 95% CI, 1.23-2.63; P = .003). The average attributable fraction of child exposure explaining ARTI was 10% (95% CI, 5%-15%). Conclusions One of 10 ARTI in community-dwelling older adults is attributable to exposure to preschool children living outside of the household. Clinical Trials Registration NCT03621930.

Published
2021

46. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe

Author

Mao, Zhuxin, primary, Li, Xiao, additional, Dacosta-Urbieta, Ana, additional, Billard, Marie-Noëlle, additional, Wildenbeest, Joanne, additional, Korsten, Koos, additional, Martinón-Torres, Federico, additional, Heikkinen, Terho, additional, Cunningham, Steve, additional, Snape, Matthew D., additional, Robinson, Hannah, additional, Pollard, Andrew J., additional, Postma, Maarten, additional, Dervaux, Benoit, additional, Hens, Niel, additional, Bont, Louis, additional, Bilcke, Joke, additional, and Beutels, Philippe, additional

Published
2023
Full Text
View/download PDF

47. T cells, more than antibodies, may prevent symptoms developing from respiratory syncytial virus infections in older adults

Author

Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Infection & Immunity, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Salaun, Bruno, De Smedt, Jonathan, Vernhes, Charlotte, Moureau, Annick, Öner, Deniz, Bastian, Arangassery Rosemary, Janssens, Michel, Balla-Jhagjhoorsingh, Sunita, Aerssens, Jeroen, Lambert, Christophe, Coenen, Samuel, Butler, Christopher C, Drysdale, Simon B, Wildenbeest, Joanne G, Pollard, Andrew J, Openshaw, Peter J M, Bont, Louis, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, Infection & Immunity, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Salaun, Bruno, De Smedt, Jonathan, Vernhes, Charlotte, Moureau, Annick, Öner, Deniz, Bastian, Arangassery Rosemary, Janssens, Michel, Balla-Jhagjhoorsingh, Sunita, Aerssens, Jeroen, Lambert, Christophe, Coenen, Samuel, Butler, Christopher C, Drysdale, Simon B, Wildenbeest, Joanne G, Pollard, Andrew J, Openshaw, Peter J M, and Bont, Louis

Published
2023

48. The impact of variant and vaccination on SARS-CoV-2 symptomatology:three prospective household cohorts

Author

Westerhof, Ilse, de Hoog, Marieke, Ieven, Margareta, Lammens, Christine, van Beek, Janko, Rozhnova, Ganna, Eggink, Dirk, Euser, Sjoerd, Wildenbeest, Joanne, Duijts, Liesbeth, van Houten, Marlies, Goossens, Herman, Giaquinto, Carlo, Bruijning‑Verhagen, Patricia, Westerhof, Ilse, de Hoog, Marieke, Ieven, Margareta, Lammens, Christine, van Beek, Janko, Rozhnova, Ganna, Eggink, Dirk, Euser, Sjoerd, Wildenbeest, Joanne, Duijts, Liesbeth, van Houten, Marlies, Goossens, Herman, Giaquinto, Carlo, and Bruijning‑Verhagen, Patricia

Abstract

Objectives: We compared age-stratified SARS-CoV-2 symptomatology of wild-type/Alpha vs Omicron BA.1/BA.2 variant infected individuals and the impact of COVID-19 booster vaccination on Omicron symptom burden. Methods: Data from three European prospective household cohorts were used (April 2020 to April 2021 and January to March 2022). Standardized outbreak protocols included (repeated) polymerase chain reaction testing, paired serology, and daily symptom scoring for all household members. Comparative analyses were performed on 346 secondary household cases from both periods. Results: Children <12 years (all unvaccinated) experienced more symptoms and higher severity scores during Omicron compared with wild-type/Alpha period (P ≤0.01). In adults, Omicron disease duration and severity were reduced (P ≤ 0.095). Omicron was associated with lower odds for loss of smell or taste (adjusted odds ratio [aOR]: 0.14; 95% CI 0.03-0.50) and higher but non-significant odds for upper respiratory symptoms, fever, and fatigue (aORs: 1.85-2.23). No differences were observed in disease severity or duration between primary vs booster series vaccinated adults (P ≥0.12). Conclusion: The Omicron variant causes higher symptom burden in children compared with wild-type/Alpha and lower in adults, possibly due to previous vaccination. A shift in symptoms occurred with reduction in loss of smell/taste for Omicron. No additional effect of booster vaccination on Omicron symptom burden was observed.

Published
2023

49. Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children from Wild-type to Population Immunity: A Prospective Multicenter Cohort Study with Real-time Reporting

Author

Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Infectieziekten patientenzorg, Infectieziekten onderzoek2 (Wildenbeest), Tulling, Adam J., Lugthart, Gertjan, Mooij, Miriam G., Brackel, Caroline L.H., Terheggen-Lagro, Suzanne W.J., Oostenbrink, Rianne, Buysse, Corinne M.P., Hashimoto, Simone, Armbrust, Wineke, Bannier, Michiel A.G.E., Bekhof, Jolita, Van Gameren-Oosterom, Helma B., Hendriks, Han, Van Houten, Marlies A., Van Der Linden, Jan W., Lebon, Ankie, Van Onzenoort-Bokken, Lonneke, Tramper-Stranders, Gerdien A., Van Veen, Mirjam, Von Asmuth, Erik G.J., Buddingh, Emilie P., Van Der Aa, Leontien B., Van Aerde, Koen J., Auffarth-Smedema, Bettina, Bart, Ingeborg Y., Beek, Cherise, Bechan, Gitanjali I., Van Den Berg, J. Merlijn, Boonstra, Venje H., Breukels, Mijke, Brinkman, Danielle M.C., Bruijning-Verhagen, Patricia C.J.L., De Crom, Stephanie C., Ernst-Kruis, Margot R., Fraaij, Pieter L.A., Goris, Joyce, Groeneweg, Michael, Gruppen, Mariken, Hammer, Sanne C., Hissink Muller, Petra C.E., Homan-Van Der Veen, Jenneke, Jacobs, Monique A.M., Kamps, Arvid W.A., Ketharanathan, Naomi, Van Der Kuip, Martijn, Kuijpers, Taco W., Legger, Elizabeth G., Lo-A-Njoe, Shirley, Manshande, Meindert E., Miedema, Carien J., Obihara, Charlie C., Olivieira, Gideon O., Oudshoorn, Annemarie, Peeters, Esther J.E., Petru, Ronald, Pijnenburg, Marielle W.H., Rook, Denise, Schilleman, Kim, Schopmeijer, Rian, Slotboom, David, Van Der Steen, Manouk, Stol, Kim, Thomasse, Yolande E.M., Tissing, Wim J.E., Van Den Tweel, Xandra W., Vastert, Sebastiaan J., Verbeek, Anne B., Vernooij-Van Langen, Annette M.M., Wieringa, Jantien W., Wildenbeest, Joanne G., De Wildt, Saskia N., Van Woerden, Christiaan, Epi Infectieziekten Team 1, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Infectieziekten patientenzorg, Infectieziekten onderzoek2 (Wildenbeest), Tulling, Adam J., Lugthart, Gertjan, Mooij, Miriam G., Brackel, Caroline L.H., Terheggen-Lagro, Suzanne W.J., Oostenbrink, Rianne, Buysse, Corinne M.P., Hashimoto, Simone, Armbrust, Wineke, Bannier, Michiel A.G.E., Bekhof, Jolita, Van Gameren-Oosterom, Helma B., Hendriks, Han, Van Houten, Marlies A., Van Der Linden, Jan W., Lebon, Ankie, Van Onzenoort-Bokken, Lonneke, Tramper-Stranders, Gerdien A., Van Veen, Mirjam, Von Asmuth, Erik G.J., Buddingh, Emilie P., Van Der Aa, Leontien B., Van Aerde, Koen J., Auffarth-Smedema, Bettina, Bart, Ingeborg Y., Beek, Cherise, Bechan, Gitanjali I., Van Den Berg, J. Merlijn, Boonstra, Venje H., Breukels, Mijke, Brinkman, Danielle M.C., Bruijning-Verhagen, Patricia C.J.L., De Crom, Stephanie C., Ernst-Kruis, Margot R., Fraaij, Pieter L.A., Goris, Joyce, Groeneweg, Michael, Gruppen, Mariken, Hammer, Sanne C., Hissink Muller, Petra C.E., Homan-Van Der Veen, Jenneke, Jacobs, Monique A.M., Kamps, Arvid W.A., Ketharanathan, Naomi, Van Der Kuip, Martijn, Kuijpers, Taco W., Legger, Elizabeth G., Lo-A-Njoe, Shirley, Manshande, Meindert E., Miedema, Carien J., Obihara, Charlie C., Olivieira, Gideon O., Oudshoorn, Annemarie, Peeters, Esther J.E., Petru, Ronald, Pijnenburg, Marielle W.H., Rook, Denise, Schilleman, Kim, Schopmeijer, Rian, Slotboom, David, Van Der Steen, Manouk, Stol, Kim, Thomasse, Yolande E.M., Tissing, Wim J.E., Van Den Tweel, Xandra W., Vastert, Sebastiaan J., Verbeek, Anne B., Vernooij-Van Langen, Annette M.M., Wieringa, Jantien W., Wildenbeest, Joanne G., De Wildt, Saskia N., and Van Woerden, Christiaan

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results